Presidio Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:7
Trial Phases
2 Phases
Phase 1:6
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Phase 2
1 (14.3%)Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
Phase 1
Completed
- Conditions
- Pharmacokinetic Assessments in Healthy Volunteers
- Interventions
- Drug: PPI-668 tabletDrug: PPI-668 capsule
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02258321
- Locations
- 🇺🇸
Buffalo Clinical Research Center, Buffalo, New York, United States
Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations
Phase 1
Completed
- Conditions
- Pharmacokinetic Assessments in Healthy Volunteers
- Interventions
- Drug: PPI-668 capsuleDrug: PPI-668 tablet
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01979484
- Locations
- 🇺🇸
Buffalo Clinical Research Center, Buffalo, New York, United States
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT01928147
- Locations
- 🇬🇧
Investigational site, Nottingham, United Kingdom
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: BI 207127 Dose 1Drug: BI 207127 Dose 2Drug: BI 207127 Placebo
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01859962
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole
Phase 1
Completed
- Conditions
- Pharmacokinetic Assessments in Healthy Volunteers
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Presidio Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01786382
- Locations
- 🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States
- Prev
- 1
- 2
- Next
News
No news found